Can You Help Antisense Pharma’s Sapphire Study?
If you, or someone you know, has been diagnosed with recurrent or refractory anaplastic astrocytoma, and would like to take part in a Phase III trial to compare trabedersen (AP 12009) with standard chemotherapies, then Antisense Pharma would like to hear from you.
Phase III trials are large, multi-centre trials which aim at achieving a definitive assessment of a drug’s performance compared with the “gold standard” existing treatments. They are the last trials to take place before a drug is submitted to regulatory bodies for approval.
You can read Antisense Pharma’s full-length account of the trial by clicking here.
Details on how to apply for enrollment into the study can be read by clicking here. This page also includes the relevant email address at Antisense Pharma for applications.
You can download Antisense Pharma’s official press release about the trial by clicking on the following link:В antisense_pm_sapphire_fach_en (you will need either Adobe Reader or Foxit Reader on your computer to open the file. Most computers will already have one or the other installed, but follow the links if yours does not).
September 14, 2009
Posted in: News from BTA
<
